SCHEMBL4138666

SCHEMBL4138666

Cc1c(NS(C)(=O)=O)cc(C(C)(C)C)c(O)c1C(=O)Nc1ccc(C#N)cc1OC(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 1/20 0.39
CNR2 P34972 1/20 0.36
PGR P06401 1/20 0.35
PTGFR P43088 1/20 0.34
PDK1 Q15118 1/20 0.34
PDK2 Q15119 1/20 0.34
PDK3 Q15120 1/20 0.34
PDK4 Q16654 1/20 0.34
IDH1 O75874 1/20 0.34
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
HRH4 Q9H3N8 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SLC22A12 Q96S37 2/20 0.33
TBXA2R P21731 2/20 0.33
TMPRSS4 Q9NRS4 1/20 0.32
PLA2G7 Q13093 1/20 0.32
BACE2 Q9Y5Z0 1/20 0.32
XDH P47989 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4146555 0.91 PGR (0.45) GCGRCNR2PGRPTGFRPDK1
SCHEMBL4133940 0.91 GCGR (0.36) GCGRCNR2PGRPTGFRPDK1
SCHEMBL4146334 0.90 CNR2 (0.38) GCGRCNR2PGRPTGFRPDK1
SCHEMBL4140219 0.89 GCGR (0.38) GCGRCNR2PTGFRPDK1PDK2
SCHEMBL4154884 0.89 PGR (0.40) GCGRCNR2PGRALDH1A1
SCHEMBL4150028 0.87 GCGR (0.39) GCGRCNR2PTGFRPDK1PDK2
SCHEMBL4149540 0.87 GCGR (0.39) GCGRCNR2PTGFRPDK1PDK2
SCHEMBL4146506 0.86 GCGR (0.39) GCGRPTGFRPDK1PDK2PDK3
SCHEMBL3170148 0.86 PTGFR (0.39) GCGRCNR2PTGFRPDK1PDK2
SCHEMBL4136944 0.86 PDK1 (0.42) GCGRCNR2PTGFRPDK1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062396-A1 Novel Haloalkoxy-Substituted Salicylic Anilides NOVO NORDISK A/S (DK) 2009-03-05 US claimed
EP-1888508-A2 NOVEL HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES NOVO NORDISK A/S (DK) 2008-02-20 EP claimed
WO-2006125781-A2 HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES NOVO NORDISK A/S (DK) 2006-11-30 WO claimed
US-20090062396-A1 Novel Haloalkoxy-Substituted Salicylic Anilides NOVO NORDISK A/S (DK) 2009-03-05 US disclosed
EP-1888508-A2 NOVEL HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES NOVO NORDISK A/S (DK) 2008-02-20 EP disclosed
WO-2006125781-A2 HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES NOVO NORDISK A/S (DK) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062396-A1 Novel Haloalkoxy-Substituted Salicylic Anilides FABP4, HDHD5, HSPD1 GCGR 1042/4885CNR2 169/4885PGR 4874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.